Human IgG1 broadly neutralizing monoclonal antibody against HIV-1 Env with LS Fc mutations to increase FcRn binding and extend half-life. It targets the gp120 CD4-binding site to neutralize diverse HIV-1 strains, block gp120 engagement with CD4/co-receptors to prevent viral entry, and via Fc effector functions (ADCC/ADCP) may promote clearance of Env-expressing infected cells.